Articles published by Vistagen
![](https://mms.businesswire.com/media/20240813123148/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update
August 13, 2024
From Vistagen
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20240806711001/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024
August 06, 2024
From Vistagen
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20240709110616/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
July 09, 2024
From Vistagen
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20240627985985/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
![](https://mms.businesswire.com/media/20240611760116/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
![](https://mms.businesswire.com/media/20240607082140/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
![](https://mms.businesswire.com/media/20240529702427/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
![](https://mms.businesswire.com/media/20240523119550/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
May 23, 2024
From Vistagen
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20240507196395/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
![](https://mms.businesswire.com/media/20240425871950/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
![](https://mms.businesswire.com/media/20240409260263/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
![](https://mms.businesswire.com/media/20240401402849/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
![](https://mms.businesswire.com/media/20240311902490/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Vistagen to Present at Stifel 2024 Virtual CNS Days
March 11, 2024
From Vistagen
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20240228708023/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
February 28, 2024
From Vistagen
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20240213784404/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
February 13, 2024
From Vistagen
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20240206380065/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
![](https://mms.businesswire.com/media/20231227642635/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
December 27, 2023
From Vistagen
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20231109410625/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
November 09, 2023
From Vistagen
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20231108051546/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Vistagen to Present at Stifel 2023 Healthcare Conference
November 08, 2023
From Vistagen
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20231107516146/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
November 07, 2023
From Vistagen
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20231106711502/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023
November 06, 2023
From Vistagen
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20231005492188/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 05, 2023
From Vistagen
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20230912021668/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
![](https://mms.businesswire.com/media/20230905339975/en/1881037/22/Fuji_Pharma_Logo.jpg)
![](https://mms.businesswire.com/media/20230822149790/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Vistagen Appoints Cindy Anderson as Chief Financial Officer
August 22, 2023
From Vistagen
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20230810272661/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
![](https://mms.businesswire.com/media/20230808331013/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023
August 08, 2023
From Vistagen
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20230807764660/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
![](https://mms.businesswire.com/media/20230716914719/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.